Novartis Plumps For Share Buybacks Before Bolt-On M&A
$15bn Allocated For Scheme
The Basel-headquartered giant has decided to spend a major chunk of its $20.7bn windfall from the sale of its stake in Roche on a stock repurchasing program up to the end of 2023, disappointing some observers who wanted to see big licensing deals or acquisitions.
